Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apraclonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apraclonidine SCHEMBL8762489 | 1.00 | BLM (0.39) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL34127 | 0.98 | CYP3A4 (0.39) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL20840496 | 0.98 | CYP3A4 (0.39) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616253 | 0.96 | CYP3A4 (0.38) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616315 | 0.88 | THRB (0.34) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616231 | 0.88 | THRB (0.42) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL8891156 | 0.88 | THRB (0.34) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616102 | 0.87 | THRB (0.41) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616234 | 0.85 | THRB (0.32) | BLMCYP3A4ALDH1A1TSHRADRA2A | |
| Apraclonidine SCHEMBL22616133 | 0.83 | KDM1A (0.32) | TSHRADRA2AADRA2BADRA2CNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683616-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | Alcon Inc. (CH) | 2026-01-28 | — | — | EP | claimed |
| WO-2024194763-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | ALCON INC. (CH) | 2024-09-26 | — | — | WO | claimed |
| US-20240307355-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | ALCON RESEARCH, LLC | 2024-09-19 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-11206977-B2 | Vision test for determining retinal disease progression | THE TRUSTEES OF THE UNIVERSITY OF PENNYSLVANIA (US) | 2021-12-28 | — | — | US | claimed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| WO-2020018498-A1 | CYCLODEXTRIN FORMULATIONS | ALDEYRA THERAPEUTICS, INC. (US) | 2020-01-23 | — | — | WO | claimed |
| CN-104557716-B | A kind of α23 adrenergic receptor agonists Apraclonidine Hydrochloride and preparation method thereof | 东华大学 | 2017-12-22 | — | — | CN | claimed |
| US-20170354324-A1 | VISION TEST FOR DETERMINING RETINAL DISEASE PROGRESSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-12-14 | — | — | US | claimed |
| US-9371387-B2 | Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-06-21 | — | — | US | claimed |
| WO-2010129294-A2 | SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH AND METHODS THEREOF | SCHULZ THOMAS C (US) | 2010-11-11 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5612364-A | INTRAOCULAR HYPERTENSION | ALCON LABORATORIES, INC. (US) | 1997-03-18 | — | — | US | claimed |
| US-5212168-A | Corticosteriod, beta adrenergic agent | NEW ENGLAND MEDICAL CENTER HOSPITAL, INC. (US) | 1993-05-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | ADRA2A 545/4885ADRA2B 994/4885ADRA2C 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.